Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;28(7):409.e1-409.e10.
doi: 10.1016/j.jtct.2022.04.012. Epub 2022 Apr 18.

Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes

Rachel Phelan  1 , Min Chen  2 , Caitrin Bupp  3 , Yung-Tsi Bolon  3 , Larisa Broglie  4 , Janet Brunner-Grady  2 , Linda J Burns  5 , Saurabh Chhabra  6 , Debra Christianson  3 , Rachel Cusatis  2 , Steven M Devine  3 , Anita D'Souza  2 , Mary Eapen  2 , Mehdi Hamadani  6 , Mary Hengen  3 , Stephanie J Lee  7 , Amy Moskop  2 , Kristin M Page  4 , Marcelo Pasquini  2 , Waleska S Pérez  2 , Marcie Riches  2 , Doug Rizzo  2 , Wael Saber  2 , Stephen R Spellman  3 , Heather E Stefanski  3 , Patricia Steinert  2 , Daniel Weisdorf  8 , Mary Horowitz  2 , Jeffery J Auletta  3 , Bronwen E Shaw  2 , Mukta Arora  9
Affiliations

Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes

Rachel Phelan et al. Transplant Cell Ther. 2022 Jul.

Abstract

Hematopoietic cell transplantation (HCT) has been successfully used to treat many malignant and nonmalignant conditions. As supportive care, donor selection, and treatment modalities evolve, documenting HCT trends and outcomes is critical. This report from the Center for International Blood and Marrow Transplant Research (CIBMTR) provides an update on current transplantation activity and survival rates in the United States. Additional data on the use and outcomes of HCT in the adolescent and young adult (AYA) population are included. AYA patients more frequently receive peripheral blood stem cell grafts than pediatric patients, which may reflect differences in practice in pediatric versus adult treatment centers. The proportions of donor types also differ those in adult and pediatric populations. Outcomes for patients in the AYA age range are similar to those of pediatric patients for acute myelogenous leukemia but worse for acute lymphoblastic leukemia. Outcomes for both leukemias are better in AYA patients compared with older adults. Comparing the time periods 2000 to 2009 and 2010 to 2019 revealed significant improvement in overall survival across the age spectrum, but the greatest improvement in the AYA age group.

Keywords: Activity; Adolescent and young adult; Hematopoietic cell transplantation; Summary slides.

PubMed Disclaimer

Figures

Figure 1a:
Figure 1a:. Estimated annual number of HCT recipients in the United States by transplant type, overall.
Figure 1b:
Figure 1b:. Estimated annual number of HCT recipients in the United States by transplant type, adult recipients (≥ 18 years) in the United States.
Figure 1c:
Figure 1c:. Estimated annual number of HCT recipients in the United States by transplant type, pediatric recipients (<18 years) in the United States.
Figure 1d:
Figure 1d:. Estimated annual number of HCT recipients in the United States by transplant type, AYA recipients (15-≤39 years) in the United States.
Figure 2a:
Figure 2a:. Indications for HCT for adult recipients (≥ 18 years) in the United States in 2019.
Figure 2b:
Figure 2b:. Indications for HCT for pediatric recipients (<18 years) in the United States in 2019.
Figure 2c:
Figure 2c:. Indications for HCT for AYA recipients (15-≤39 years) in the United States in 2019.
Figure 3a:
Figure 3a:. Trends in allogeneic HCT by recipient age in the United States.
Figure 3b:
Figure 3b:. Trends in autologous HCT by recipient age in the United States.
Figure 4:
Figure 4:. Allogeneic HCT in the United States by donor type.
Figure 5a:
Figure 5a:. Matched related donor allogeneic HCT in the United States in patients 15-≤39 years by graft source.
Figure 5b:
Figure 5b:. Unrelated donor allogeneic HCT in the United States in patients 15-≤39 years by graft source.
Figure 6a:
Figure 6a:. Haploidentical donor allogeneic HCT activity in the United States, by graft type, adults (>18 years).
Figure 6b:
Figure 6b:. Haploidentical donor allogeneic HCT activity in the United States, by graft type, pediatric (<18 years).
Figure 6c:
Figure 6c:. Haploidentical donor allogeneic HCT activity in the United States, by graft type, AYA (15–39 years).
Figure 7a:
Figure 7a:. Trends in allogeneic HCT for AML by disease status in the United States.
Figure 7b:
Figure 7b:. Trends in allogeneic HCT for ALL by disease status in the United States.
Figure 8a:
Figure 8a:. Allogeneic HCT for different races over time in the United States.
Figure 8b:
Figure 8b:. Autologous HCT for different races over time in the United States.
Figure 9a:
Figure 9a:. Causes of death after AYA (15–39 years) matched related HCT in the United States, 2017–2018.
Figure 9b:
Figure 9b:. Causes of death after AYA (15–39 years) haploidentical HCT in the United States, 2017–2018.
Figure 9c:
Figure 9c:. Causes of death after AYA (15–39 years) unrelated donor HCT in the United States, 2017–2018.
Figure 10:
Figure 10:. Causes of death after AYA (15–39 years) autologous HCT in the United States, 2017–2018.
See this image and copyright information in PMC

References

    1. Kanate AS, Majhail NS, Savani BN, et al. : Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 26:1247–1256, 2020 - PubMed
    1. D’Souza A, Fretham C, Lee SJ, et al. : Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant 26:e177–e182, 2020 - PMC - PubMed
    1. Geiger AM, Castellino SM: Delineating the age ranges used to define adolescents and young adults. J Clin Oncol 29:e492–3, 2011 - PubMed
    1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Adolescent and young adult oncology version 1.2022. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 1 September 2021.
    1. Mehta PA, Rotz SJ, Majhail NS: Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. Biol Blood Marrow Transplant 24:e11–e19, 2018 - PubMed

Publication types